Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Tables)

v3.24.0.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2023
INCOME TAXES  
Schedule of components of the entity's deferred tax assets

As of December 31,

 

    

2023

    

2022

 

Deferred tax assets

Net operating loss carryforwards

$

229,967

$

230,373

Orphan drug and research and development credits

 

62,457

 

68,646

Capitalized research and development credits

21,017

15,680

Deferred revenue

 

11,223

 

11,234

Deferred compensation

 

10,365

 

9,620

Lease liabilities

244

504

Other, net

 

3,654

 

2,494

Deferred tax liabilities

Operating lease right-of-use asset

(215)

(461)

Others

(81)

(439)

Total net deferred tax assets

338,631

337,651

Less: valuation allowance

 

(338,631)

 

(337,651)

Deferred tax assets, net of allowance

$

$

Schedule of reconciliation of the statutory federal income tax rate to the effective tax rate

Year Ended December 31,

 

    

2023

    

2022

    

2021

 

Federal statutory tax rate

 

(21.0)

%  

(21.0)

%  

(21.0)

%

State, net of federal benefit

0.1

%  

0.0

%  

2.8

%

Valuation allowance

 

13.9

%  

20.2

%  

27.5

%

Stock compensation

5.3

%  

2.5

%  

5.6

%

Orphan drug and research and development credits

0.2

%  

(2.6)

%  

(14.0)

%

Other, net

 

1.5

%  

1.0

%  

2.7

%  

Effective tax rate

 

0.0

%  

0.1

%  

3.6

%  

Schedule of activity related to the entity's gross unrecognized tax benefits

The following table summarizes the activity related to our gross unrecognized tax benefits (in thousands):

Year Ended December 31,

 

    

2023

    

2022

    

2021

 

Balance at the beginning of the year

$

9,426

$

9,186

$

8,901

Decrease related to prior year tax positions

 

(843)

 

 

Increase related to current year tax positions

 

89

 

240

 

285

Balance at the end of the year

$

8,672

$

9,426

$

9,186